Please provide your email address to receive an email when new articles are posted on . This analysis focused on adults with moderate to severe COPD without an exacerbation during the ENHANCE trials.

Acquisition strengthens Merck’s cardio-pulmonary portfolio with addition of Ohtuvayre® (ensifentrine), a first-in-class COPD maintenance treatment, that is expected to grow into the next decade Merck ...

LONDON and RALEIGH, N.C., Oct. 06, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a biopharmaceutical company focused on respiratory diseases, which entered into a ...

Acquisition aligns with Merck’s science-led business development strategy and expands pipeline and portfolio of treatments for cardio-pulmonary diseases Through this acquisition Merck will add ...

Merck & Co. Inc. (NYSE:MRK) agreed on Wednesday to acquire Verona Pharma plc (NASDAQ:VRNA) for $107 per American Depository Share (ADS) for a total transaction value of approximately $10 billion. Each ...

TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” first-quarter 2025 investor letter. A copy of the letter can be downloaded here.

Verona Pharma plc has announced the upcoming presentation of ten posters at the American Thoracic Society Conference 2025, highlighting analyses from its Phase 3 ENHANCE studies of Ohtuvayre ...

Verona Pharma plc (NASDAQ:VRNA – Free Report) – Stock analysts at Roth Capital dropped their Q1 2026 EPS estimates for shares of Verona Pharma in a note issued to investors on Tuesday, April 29th.

We recently published a list of 10 Best Performing Growth Stocks in 2025 In this article, we are going to take a look at where Verona Pharma plc (NASDAQ:VRNA) stands against other best performing ...

Verona Pharma (NASDAQ:VRNA – Free Report) had its price objective increased by HC Wainwright from $60.00 to $75.00 in a report issued on Friday,Benzinga reports. The firm currently has a buy rating on ...

LONDON and RALEIGH, N.C., Jan. 07, 2025 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a biopharmaceutical company focused on respiratory diseases, announces ...

Optimistic projections are so, well, optimistic. Who’s to say they’ll pan out that way? Every year MM+M issues its top crop of launches to watch in the coming months. This time, we’ve followed up to ...